Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2025)

Enanta Pharmaceuticals filings provide 9 years of Gains from Sales and Divestitures readings, the most recent being $68000.0 for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 172.0% to $68000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $68000.0, a 172.0% increase, with the full-year FY2025 number at $68000.0, up 172.0% from a year prior.
  • Gains from Sales and Divestitures hit $68000.0 in Q3 2025 for Enanta Pharmaceuticals, roughly flat from $68000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $145000.0 in Q1 2025 to a low of $18000.0 in Q1 2022.
  • Median Gains from Sales and Divestitures over the past 5 years was $45000.0 (2021), compared with a mean of $47764.7.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 1400.0% in 2021 and later tumbled 64.29% in 2024.
  • Enanta Pharmaceuticals' Gains from Sales and Divestitures stood at $29000.0 in 2021, then skyrocketed by 93.1% to $56000.0 in 2022, then increased by 25.0% to $70000.0 in 2023, then crashed by 64.29% to $25000.0 in 2024, then skyrocketed by 172.0% to $68000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $68000.0 (Q3 2025), $68000.0 (Q2 2025), and $145000.0 (Q1 2025) per Business Quant data.